SCHEMBL24906181

SCHEMBL24906181

CONC(=O)c1c(Nc2ccc(C)cc2F)sc2nc(C)ccc12

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.39
USP25 Q9UHP3 3/20 0.37
MAP2K1 Q02750 4/20 0.37
USP28 Q96RU2 4/20 0.36
IKBKB O14920 1/20 0.36
LIMK1 P53667 1/20 0.36
MAP2K2 P36507 1/20 0.35
MAPT P10636 2/20 0.35
RXFP1 Q9HBX9 2/20 0.35
POLB P06746 1/20 0.35
FLT1 P17948 1/20 0.35
KDR P35968 1/20 0.35
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
DHODH Q02127 1/20 0.34
SYK P43405 1/20 0.34
TP53 P04637 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22045818 0.90 MAP2K1 (0.46) MAP2K1USP28MAP2K2
SCHEMBL24906352 0.89 MAP2K1 (0.39) CSF1RUSP25MAP2K1USP28MAP2K2
SCHEMBL24350870 0.88 MAP2K1 (0.44) MAP2K1MAP2K2
SCHEMBL24350841 0.86 MEN1 (0.39) USP25MAP2K1IKBKBLIMK1MAP2K2
SCHEMBL26047259 0.86 MAP2K1 (0.42) USP25MAP2K1MAP2K2
SCHEMBL22045814 0.85 MAP2K1 (0.43) USP25MAP2K1USP28MAP2K2FLT1
SCHEMBL26047253 0.84 MAP2K1 (0.47) MAP2K1MAP2K2
SCHEMBL24906170 0.84 MAP2K1 (0.47) MAP2K1MAP2K2
SCHEMBL24906315 0.84 MAP2K1 (0.47) MAP2K1MAP2K2
SCHEMBL24906189 0.84 CSF1R (0.43) CSF1RMAP2K1IKBKBMAP2K2FLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4233834-A2 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS NFlection Therapeutics, Inc. (US) 2023-08-30 EP disclosed
EP-4233865-A2 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS NFlection Therapeutics, Inc. (US) 2023-08-30 EP disclosed
US-20230013227-A1 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS NFLECTION THERAPEUTICS, INC. 2023-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230013227-A1 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS HTR3C, NDUFA13, NDUFAF3 CSF1R 2681/4885USP25 2722/4885MAP2K1 4087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.